Novo Nordisk ready to go toe to toe with Ascendis
Should Novo Nordisk end up in direct competition with Ascendis Pharma on the growth hormone market, the Danish pharmaceutical giant has an arsenal ready, including a network of doctors and payers, says CEO Lars Fruergaard Jørgensen.
by ANDREAS LØNSTRUP, translated by daniel pedersen
The stage is being set for a battle of the Danes, with pharmaceutical giant Novo Nordisk in one corner and biotech firm Ascendis Pharma, which is on the upswing, in the other.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
